207 related articles for article (PubMed ID: 15538745)
1. 5alpha-dihydrotestosterone inhibits 1alpha,25-dihydroxyvitamin D3-induced expression of CYP24 in human prostate cancer cells.
Lou YR; Nazarova N; Talonpoika R; Tuohimaa P
Prostate; 2005 May; 63(3):222-30. PubMed ID: 15538745
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells.
Qiao S; Pennanen P; Nazarova N; Lou YR; Tuohimaa P
J Steroid Biochem Mol Biol; 2003 May; 85(1):1-8. PubMed ID: 12798352
[TBL] [Abstract][Full Text] [Related]
3. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
[TBL] [Abstract][Full Text] [Related]
4. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
Zhao XY; Peehl DM; Navone NM; Feldman D
Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
[TBL] [Abstract][Full Text] [Related]
5. Androgen enhances the antiproliferative activity of vitamin D3 by suppressing 24-hydroxylase expression in LNCaP cells.
Lou YR; Tuohimaa P
J Steroid Biochem Mol Biol; 2006 Apr; 99(1):44-9. PubMed ID: 16524720
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
7. Regulation of aromatase and 5alpha-reductase by 25-hydroxyvitamin D(3), 1alpha,25-dihydroxyvitamin D(3), dexamethasone and progesterone in prostate cancer cells.
Lou YR; Murtola T; Tuohimaa P
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):151-7. PubMed ID: 15862960
[TBL] [Abstract][Full Text] [Related]
8. Clonal differences in expression of 25-hydroxyvitamin D(3)-1alpha-hydroxylase, of 25-hydroxyvitamin D(3)-24-hydroxylase, and of the vitamin D receptor in human colon carcinoma cells: effects of epidermal growth factor and 1alpha,25-dihydroxyvitamin D(3).
Bareis P; Kállay E; Bischof MG; Bises G; Hofer H; Pötzi C; Manhardt T; Bland R; Cross HS
Exp Cell Res; 2002 Jun; 276(2):320-7. PubMed ID: 12027461
[TBL] [Abstract][Full Text] [Related]
9. A 24-phenylsulfone analog of vitamin D inhibits 1alpha,25-dihydroxyvitamin D(3) degradation in vitamin D metabolism-competent cells.
Lechner D; Manhardt T; Bajna E; Posner GH; Cross HS
J Pharmacol Exp Ther; 2007 Mar; 320(3):1119-26. PubMed ID: 17182978
[TBL] [Abstract][Full Text] [Related]
10. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1999 Mar; 140(3):1205-12. PubMed ID: 10067845
[TBL] [Abstract][Full Text] [Related]
11. Mouse vitamin D-24-hydroxylase: molecular cloning, tissue distribution, and transcriptional regulation by 1alpha,25-dihydroxyvitamin D3.
Akeno N; Saikatsu S; Kawane T; Horiuchi N
Endocrinology; 1997 Jun; 138(6):2233-40. PubMed ID: 9165006
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic regulation of vitamin D hydroxylase expression and activity in normal and malignant human prostate cells.
Khorchide M; Lechner D; Cross HS
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):167-72. PubMed ID: 15860259
[TBL] [Abstract][Full Text] [Related]
13. Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse.
Masuda S; Byford V; Arabian A; Sakai Y; Demay MB; St-Arnaud R; Jones G
Endocrinology; 2005 Feb; 146(2):825-34. PubMed ID: 15498883
[TBL] [Abstract][Full Text] [Related]
14. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D.
Flanagan JN; Young MV; Persons KS; Wang L; Mathieu JS; Whitlatch LW; Holick MF; Chen TC
Anticancer Res; 2006; 26(4A):2567-72. PubMed ID: 16886665
[TBL] [Abstract][Full Text] [Related]
16. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
17. Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer.
Pang ST; Flores-Morales A; Skoog L; Chuan YC; Nordstedt G; Pousette A
Oncol Rep; 2004 Jun; 11(6):1187-92. PubMed ID: 15138554
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines.
Miller GJ; Stapleton GE; Hedlund TE; Moffat KA
Clin Cancer Res; 1995 Sep; 1(9):997-1003. PubMed ID: 9816072
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
Wang LG; Liu XM; Kreis W; Budman DR
Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor-mediated repression of novel target genes.
Prescott J; Jariwala U; Jia L; Cogan JP; Barski A; Pregizer S; Shen HC; Arasheben A; Neilson JJ; Frenkel B; Coetzee GA
Prostate; 2007 Sep; 67(13):1371-83. PubMed ID: 17624924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
